RET and non-small cell lung carcinoma: Earlier multi-kinase inhibitors (MKIs) such as cabozantinib and vandetanib have been tested in clinical trials for the treatment of RET fusion-positive NSCLC or medullary thyroid cancers (MTCs) with RET mutations10–12.